Every earnings call for GLENMARK — management tone, guidance, KPIs and promise tracking, quarter by quarter.
GLENMARK · 5 transcripts · Healthcare · latest Q3 FY26Glenmark Pharmaceuticals Limited has 5 earnings calls on record here, a Healthcare company, most recently Q3 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Consolidated Revenue 39006 million (+15% YoY); EBITDA Margin 23%. Consolidated revenue from operations was at INR39,006 million, a Y-o-Y growth of 15.1%.
Read full transcript & analysisConsolidated Revenue 60469 million (+76% YoY). Consolidated revenue grew 76% YoY to INR 60,469 million in Q2 FY26.
Read full transcript & analysisConsolidated Revenue ₹3,264 cr (+1% YoY); Net Debt ₹1,500 cr. Consolidated revenue from operations at INR 32,644 million, recording a Y-o-Y growth of 0.6%.
Read full transcript & analysisConsolidated Revenue FY25 133217 million (+13% YoY). FY25 Consolidated Revenue: INR1,33,217 million, up 12.8% YoY.
Read full transcript & analysisConsolidated Revenue ₹3,388 cr (+35% YoY); Net Debt ₹109 cr. Consolidated revenue grew 35.1% YoY to INR 3387.6 crores.
Read full transcript & analysis